Status:
ACTIVE_NOT_RECRUITING
Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)
Lead Sponsor:
University of Michigan
Collaborating Sponsors:
Amryt Pharma
Conditions:
Lipomatosis, Multiple Symmetrical
Eligibility:
All Genders
Up to 60 years
Phase:
PHASE2
Brief Summary
Participants (homozygous MFN2 \[gene that provides instructions to produce the Mitofusin 2 protein\] R707W) will be treated with Metreleptin, and effects on body composition, metabolic parameters and ...
Detailed Description
In 2024, the IRB granted an amendment that allowed for continued data collection, including adverse events, up to 5 years per participant.
Eligibility Criteria
Inclusion
- Have the clinical diagnosis of MSL and being followed at University of Michigan (cohort to be studied in this proof-of-concept study is already available at Michigan).
- Willing and able to tolerate the study procedures.
- Willing and able to tolerate blood sampling.
- Having no condition that may impede successful data collection or interfere with testing parameters.
- \<60 years of age.
- If female of childbearing potential:
- Not breastfeeding.
- Negative pregnancy test (human chorionic gonadotropin, beta subunit) at baseline.
- Can read, understand and sign approved informed consent form, communicate with study physician, and study team, and understand and comply with protocol requirements.
Exclusion
- Presence of advanced liver disease (abnormal synthetic function, prothrombin time \[PT\], or albumin) in medical records
- Evidence of other etiologies of viral hepatitis in medical records
- Presence of active hematologic, bone marrow or other abnormalities that may increase risk of bleeding in medical records.
- Presence of HIV infection in medical records.
- Presence of End-stage renal disease (ESRD), active cancer, or \>class 2 congestive heart failure based on medical history and physical examination.
- Active chronic infection (e.g., known chronic osteomyelitis or Tuberculosis \[TB\]). May have transient infections but must be free of active infection for two weeks prior to study visits.
- Unable to ambulate or tolerate trips to the University of Michigan Clinical Research Unit.
- Clinically relevant Coronary artery disease (CAD): history of stent or Coronary artery bypass graft surgery (CABG) with cardiologist confirmed angina.
- Presence of autoimmune disease.
- Hypersensitivity to metreleptin.
- General obesity not associated with congenital leptin deficiency.
- Any other condition that, in our opinion, may impede successful data collection.
Key Trial Info
Start Date :
August 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2028
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT05351164
Start Date
August 1 2023
End Date
October 1 2028
Last Update
June 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan
Ann Arbor, Michigan, United States, 48109